Details of the Drug

General Information of Drug (ID: DMCT3I8)

Drug Name
Ifosfamide
Synonyms
Cyfos; Holoxan; Ifex; Ifosfamid; Ifosfamida; Ifosfamidum; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; Isosfamide; Mitoxana; Naxamide; Ifosfamide Sterile; Iso Endoxan; A 4942; ASTA Z 4942; Holoxan 1000; MJF 9325; Z 4942; Z4942; I-Phosphamide; IFEX (TN); Ifex (TN); Ifosfamida [INN-Spanish]; Ifosfamidum [INN-Latin]; Iphosphamid(e); Iso-Endoxan; MJF-9325; Mitoxana (TN); NPFAPI-04; Z-4942; Mitoxana, Ifex, Ifosfamide; Ifosfamide (JAN/USP/INN); Ifosfamide [USAN:INN:BAN:JAN]; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; (+-)-Ifosfamid; (+-)-Ifosphamide; (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; (D,L)-Ifosfamide; (R,S)-Ifosphamide; (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3,} 2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Indication
Disease Entry ICD 11 Status REF
Adult central nervous system germ cell tumor N.A. Approved [1]
Adult teratoma N.A. Approved [1]
Advanced cancer 2A00-2F9Z Approved [1]
Extragonadal germ cell cancer N.A. Approved [1]
Extragonadal germ cell tumor N.A. Approved [1]
Kidney neoplasm N.A. Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Testicular germ cell tumor N.A. Approved [1]
Extragonadal nonseminomatous germ cell tumor N.A. Investigative [1]
Extragonadal seminoma N.A. Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
Retinoblastoma 2D02.2 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01AA06: Ifosfamide
L01AA: Nitrogen mustard analogues
L01A: ALKYLATING AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 261.079
Logarithm of the Partition Coefficient (xlogp) 0.9
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
92% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.1 mL/min/kg [5]
Elimination
10% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 15 hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 113.5897 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 1% [5]
Vd
The volume of distribution (Vd) of drug is 0.64 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Arterial disorder Not Available ELN OTFSO7PG [7]
Drug tolerance Not Available ADRA2A OTZFGOTP [7]
Metabolic disorder Not Available AMD1 OTKAGZY3 [7]
Metabolic disorder Not Available ODC1 OTNDAGRR [7]
Chemical Identifiers
Formula
C7H15Cl2N2O2P
IUPAC Name
N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
Canonical SMILES
C1CN(P(=O)(OC1)NCCCl)CCCl
InChI
InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
InChIKey
HOMGKSMUEGBAAB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3690
ChEBI ID
CHEBI:5864
CAS Number
3778-73-2
UNII
UM20QQM95Y
DrugBank ID
DB01181
TTD ID
D02TLO
INTEDE ID
DR0855
ACDINA ID
D01151
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [13]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [14]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [13]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [15]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [9]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Gene/Protein Processing [16]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [16]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Gene/Protein Processing [16]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2) OTLVN68B AAKB2_HUMAN Gene/Protein Processing [16]
ABC-type oligopeptide transporter ABCB9 (ABCB9) OTSOBOL5 ABCB9_HUMAN Gene/Protein Processing [16]
Adenylate kinase 4, mitochondrial (AK4) OTA0T02Q KAD4_HUMAN Gene/Protein Processing [16]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Gene/Protein Processing [16]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [16]
Alpha-2A adrenergic receptor (ADRA2A) OTZFGOTP ADA2A_HUMAN Drug Response [7]
ALS2 C-terminal-like protein (ALS2CL) OT8RY7TZ AL2CL_HUMAN Gene/Protein Processing [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 81 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 8.1467 10.699 5.1478 1.1731
U-937 CTRP2 4.0998 5.6832 1.5496 0.3795
THP-1 CTRP2 4.6336 6.0973 1.6016 0.1274
SU-DHL-8 CTRP2 6.9659 9.0413 5.2266 2.0129
MV4-11 CTRP2 7.1883 10.5033 4.6811 3.8619
MC116 CTRP2 7.2631 8.2256 5.7274 0.1753
HPB-ALL CTRP2 7.2844 9.1979 5.3418 1.2517
L-1236 CTRP2 7.3049 11.2435 4.4055 4.8007
SU-DHL-6 CTRP2 7.3926 9.2102 5.3937 0.9862
MHH-CALL-3 CTRP2 7.4154 10.4103 4.8707 2.8304
SU-DHL-1 CTRP2 7.4936 8.4651 5.7297 0.1091
SU-DHL-10 CTRP2 7.5266 8.3814 5.7705 0.0568
Karpas-620 CTRP2 7.551 9.1699 5.4875 0.5974
MM1.S CTRP2 7.5555 9.2682 5.4499 0.6982
AMO1 CTRP2 7.5833 8.9525 5.5866 0.3372
BV-173 CTRP2 7.5914 10.0412 5.1404 1.6556
KMS-26 CTRP2 7.6284 8.5761 5.74 0.0721
MOLM-13 CTRP2 7.7011 9.6032 5.3827 0.7937
ME1 CTRP2 7.7186 9.3027 5.5102 0.4493
Ku812 CTRP2 7.8053 10.2813 5.151 1.4284
L-363 CTRP2 7.8165 9.1475 5.6085 0.2108
NOMO-1 CTRP2 7.8398 9.1876 5.603 0.2132
HT CTRP2 7.8475 8.9428 5.6922 0.088
Reh CTRP2 7.878 9.2971 5.5781 0.2446
DEL CTRP2 7.8882 9.5863 5.4739 0.4532
EM-2 CTRP2 7.8991 9.2235 5.6129 0.1809
WSU-DLCL2 CTRP2 7.9005 8.9058 5.7233 0.0523
P31/FUJ CTRP2 7.9071 8.92 5.7208 0.0536
HEL CTRP2 7.9209 9.3221 5.5857 0.2184
MOLM-16 CTRP2 7.9437 10.5296 5.1169 1.4239
Peer CTRP2 7.9589 9.6736 5.4706 0.429
NCI-H929 CTRP2 7.9846 9.3142 5.6128 0.1601
CML-T1 CTRP2 7.9908 9.4888 5.5525 0.2542
KMS-27 CTRP2 8.0238 9.4751 5.5703 0.2144
KMM-1 CTRP2 8.028 10.1531 5.3137 0.7796
OCI-AML-2 CTRP2 8.0358 9.0888 5.7085 0.0497
P12-Ichikawa CTRP2 8.0671 9.4855 5.583 0.1834
NALM-6 CTRP2 8.0818 9.6611 5.5254 0.2734
KE-37 CTRP2 8.0856 9.4131 5.6154 0.135
KMS-34 CTRP2 8.098 9.3993 5.6247 0.1212
JURL-MK1 CTRP2 8.1072 9.5455 5.5768 0.1827
MOLT-16 CTRP2 8.1345 9.5413 5.5885 0.16
SK-MM-2 CTRP2 8.1642 9.6206 5.5716 0.1767
NCO2 CTRP2 8.1645 10.0936 5.3975 0.5007
NU-DUL-1 CTRP2 8.1688 9.7069 5.5425 0.2191
KM-H2 CTRP2 8.1732 9.8138 5.5056 0.2794
KMS-21-BM CTRP2 8.1781 9.7846 5.5181 0.2563
L-540 CTRP2 8.191 9.7134 5.5487 0.2037
PF-382 CTRP2 8.2331 9.8369 5.5205 0.2366
SU-DHL-4 CTRP2 8.2502 9.4424 5.6637 0.0615
KE-97 CTRP2 8.2638 9.6025 5.6142 0.1049
RS4;11 CTRP2 8.2683 10.0106 5.4711 0.3105
REC-1 CTRP2 8.304 10.2276 5.4051 0.4255
JVM-2 CTRP2 8.3079 10.9028 5.142 1.0798
KYO-1 CTRP2 8.3111 9.5816 5.6379 0.0757
SR CTRP2 8.3128 9.7603 5.5773 0.138
Ki-JK CTRP2 8.3569 9.7684 5.5904 0.1154
KHM-1B CTRP2 8.3948 9.9052 5.5568 0.1475
Jurkat CTRP2 8.3988 9.6146 5.657 0.0519
SUP-T11 CTRP2 8.4011 9.7796 5.6022 0.0965
JVM-3 CTRP2 8.4033 10.2443 5.4389 0.3246
PL21 CTRP2 8.4058 9.7858 5.6018 0.0963
MOLM-6 CTRP2 8.439 10.4502 5.3771 0.4301
LAMA-84 CTRP2 8.473 10.4539 5.3895 0.393
KMS-18 CTRP2 8.5027 10.5442 5.368 0.4242
RPMI-8402 CTRP2 8.5096 9.8264 5.6241 0.0647
MOLP-2 CTRP2 8.5149 13.708 4.0234 4.7341
KCL-22 CTRP2 8.5188 10.07 5.5445 0.1392
HDLM-2 CTRP2 8.5284 10.2922 5.47 0.237
EHEB CTRP2 8.5325 11.4869 5.0107 1.3077
ALL-SIL CTRP2 8.5708 9.9711 5.5967 0.0798
KMS-12-BM CTRP2 8.5711 9.9075 5.618 0.0631
P3HR-1 CTRP2 8.5742 10.0665 5.5655 0.1078
GDM-1 CTRP2 8.632 10.3075 5.5031 0.1679
TALL-1 [Human adult T-ALL] CTRP2 8.6634 10.5912 5.4144 0.2882
MHH-CALL-4 CTRP2 8.7342 10.6468 5.4215 0.258
RCH-ACV CTRP2 8.7721 10.4009 5.5212 0.1231
Ri-1 CTRP2 8.7771 11.2047 5.233 0.5957
Mono-Mac-1 CTRP2 8.9454 11.1365 5.3264 0.3527
KMS-28BM CTRP2 8.9492 11.2588 5.2831 0.4284
KMS-11 CTRP2 9.3069 11.2237 5.4294 0.1365
⏷ Show the Full List of 81 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 8.3268 10.2778 5.3956 0.4361
TE-6 CTRP2 8.0383 10.0527 5.3583 0.6573
KYSE-180 CTRP2 8.1191 10.0051 5.412 0.4885
TE-9 CTRP2 8.289 9.5708 5.6339 0.082
KYSE-70 CTRP2 8.3217 9.9097 5.5281 0.2018
TE-1 CTRP2 8.3801 10.1317 5.4708 0.2763
KYSE-410 CTRP2 8.3837 10.1135 5.4788 0.2621
TE-4 CTRP2 8.4727 10.0877 5.5215 0.1767
COLO 680N CTRP2 8.5016 9.9031 5.5956 0.0892
TE-10 CTRP2 8.5439 10.3467 5.4564 0.2539
KYSE-140 CTRP2 8.9468 11.0429 5.3607 0.2963
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MHH-NB-11 CTRP2 7.049 10.286 4.6912 4.0161
CHP-126 CTRP2 7.9467 9.6121 5.4888 0.3947
KP-N-SI9s CTRP2 8.1306 9.7411 5.5154 0.2756
NB1 CTRP2 8.1539 9.3261 5.6695 0.0675
SiMa CTRP2 8.6892 10.4943 5.4587 0.2146
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-478 CTRP2 7.4977 9.6522 5.2592 1.3372
SNU-1196 CTRP2 7.8999 9.7622 5.4107 0.5996
HuH-28 CTRP2 8.1392 9.4613 5.6181 0.1215
HuCC-T1 CTRP2 8.253 9.6784 5.584 0.1413
SNU-1079 CTRP2 8.2549 10.1853 5.4007 0.4546
SNU-245 CTRP2 8.5586 10.9724 5.2286 0.7069
SNU-308 CTRP2 8.6021 10.0827 5.5698 0.0998
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U2OS CTRP2 7.2003 9.7309 5.0522 2.3963
SJSA-1 CTRP2 8.5092 10.4544 5.4038 0.3535
CAL-78 CTRP2 8.643 10.1992 5.5445 0.1188
MHH-ES-1 CTRP2 9.1074 10.8305 5.4929 0.1041
SW1353 CTRP2 13.895 28.0394 0.6956 9.8858
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KPL-1 CTRP2 6.8193 7.611 5.7743 0.2643
HMC-1-8 CTRP2 7.7848 9.4272 5.4907 0.4631
HCC1954 CTRP2 7.8315 10.8748 4.9058 2.2432
HCC1937 CTRP2 7.8481 11.19 4.774 2.7009
CAL-148 CTRP2 8.1002 9.6095 5.5513 0.2239
HCC1806 CTRP2 8.1986 9.8651 5.4968 0.2869
MDA-MB-231 CTRP2 8.2004 10.4499 5.2743 0.7836
HDQ-P1 CTRP2 8.2681 9.9271 5.5014 0.2579
ZR-75-1 CTRP2 8.3186 9.9523 5.5118 0.2273
MCF-7 CTRP2 8.3196 9.9788 5.5026 0.2413
JIMT-1 CTRP2 8.4477 9.9642 5.5555 0.1392
CAL-51 CTRP2 8.5929 10.0484 5.5782 0.0932
HCC1143 CTRP2 8.6235 10.9875 5.2508 0.6241
HCC1395 CTRP2 8.6338 10.6523 5.3806 0.3548
CAMA-1 CTRP2 10.153 26.8912 -1.185 19.3491
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 7.6835 8.574 5.7599 0.0469
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GaMG CTRP2 4.7848 6.3456 1.5703 0.1395
SW1088 CTRP2 5.1342 6.8512 1.521 0.139
U-87MG ATCC CTRP2 6.8797 8.8484 5.2624 1.9812
SNU-626 CTRP2 6.9831 8.8842 5.3096 1.6782
SNU-489 CTRP2 7.1278 10.7133 4.5395 4.5146
KNS-81 CTRP2 7.4089 8.7612 5.5851 0.424
KNS-60 CTRP2 7.4392 8.6394 5.6449 0.2726
SNU-738 CTRP2 7.524 9.1172 5.4962 0.5902
LN-18 CTRP2 7.6237 8.773 5.6692 0.1662
SNU-466 CTRP2 7.6935 8.9305 5.6393 0.1952
NMC-G1 CTRP2 7.7489 9.2588 5.5399 0.3681
SF126 CTRP2 7.7598 9.1719 5.577 0.2869
Daoy CTRP2 7.7925 9.8088 5.3425 0.8482
SNU-201 CTRP2 7.9587 9.2343 5.6313 0.1404
SF295 CTRP2 8.0095 9.4931 5.5582 0.2386
CAS-1 CTRP2 8.126 9.6293 5.554 0.2125
GB-1 CTRP2 8.1723 9.5058 5.6147 0.1195
KALS-1 CTRP2 8.4777 10.7555 5.2774 0.6308
LN-229 CTRP2 8.6463 9.935 5.6344 0.046
ONS-76 CTRP2 8.923 10.3777 5.5812 0.0567
DBTRG-05MG CTRP2 10.6535 18.8597 2.9482 6.2272
SNU-1105 CTRP2 10.8678 22.6385 1.3401 11.3021
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-151 CTRP2 4.7411 6.1576 1.6184 0.092
EFE-184 CTRP2 4.8129 6.4145 1.5567 0.1517
HEC-1-B CTRP2 7.2729 13.8023 3.1356 9.9667
RL95-2 CTRP2 7.5128 9.2183 5.45 0.7263
HEC-265 CTRP2 7.6747 9.2682 5.5044 0.4851
HEC-251 CTRP2 7.7085 9.3037 5.5054 0.4656
HEC-50B CTRP2 7.7508 9.8551 5.3031 0.9928
HEC-108 CTRP2 7.9334 11.3716 4.7417 2.7271
JHUEM-2 CTRP2 7.9983 9.8873 5.4053 0.5617
HEC-59 CTRP2 8.0545 9.5579 5.5522 0.2354
HEC-6 CTRP2 8.2286 9.4434 5.6559 0.0702
KLE CTRP2 8.4139 10.6193 5.3024 0.603
Ishikawa (Heraklio) 02 ER- CTRP2 6.8911 8.8456 5.2708 1.9344
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TUHR10TKB CTRP2 7.2418 11.4434 4.2659 5.4538
SNU-1272 CTRP2 7.502 12.8506 3.7663 7.0829
TUHR4TKB CTRP2 7.5165 9.5043 5.3325 1.0812
769-P CTRP2 7.81 9.5731 5.4449 0.5616
KMRC-20 CTRP2 8.006 11.6201 4.6719 2.9037
VMRC-RCW CTRP2 8.3957 9.9046 5.5573 0.1467
OS-RC-2 CTRP2 8.6205 10.051 5.5869 0.0821
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-C5 CTRP2 4.9858 6.7814 1.4925 0.2061
HT-29 CTRP2 6.9375 8.795 5.3229 1.6805
HCT 116 CTRP2 6.9733 8.6321 5.4181 1.2894
DLD-1 CTRP2 7.0785 8.2346 5.644 0.4597
HT-55 CTRP2 7.3441 9.363 5.3021 1.3317
MDST8 CTRP2 7.3942 9.1094 5.4369 0.8495
LS411N CTRP2 7.5678 8.7704 5.6483 0.2188
HT115 CTRP2 7.7801 9.0971 5.6126 0.2148
COLO205 CTRP2 7.8437 9.1146 5.6307 0.168
OUMS-23 CTRP2 7.8551 9.0086 5.6722 0.1094
SW48 CTRP2 7.8678 9.2687 5.5844 0.2366
LS180 CTRP2 7.8832 10.3538 5.1605 1.3337
COLO201 CTRP2 7.8857 8.9805 5.6929 0.0814
SNU-81 CTRP2 7.9524 9.7726 5.4298 0.5256
KM12 CTRP2 7.9733 9.9057 5.387 0.6197
RKO CTRP2 8.0514 9.8501 5.4425 0.4507
SW1463 CTRP2 8.0633 9.5107 5.5726 0.2002
LS513 CTRP2 8.2039 9.5874 5.5978 0.1338
LoVo CTRP2 8.4552 10.9787 5.18 0.8847
SNU-407 CTRP2 8.4632 10.3345 5.4295 0.3221
CW-2 CTRP2 8.4644 10.0987 5.5146 0.1878
SNU-61 CTRP2 8.5588 10.2357 5.5014 0.1851
LS123 CTRP2 8.6928 10.3512 5.51 0.1483
SW620 CTRP2 8.7007 10.2348 5.5527 0.1025
SNU-C2A CTRP2 8.7691 11.7848 5.0019 1.1769
SK-CO-1 CTRP2 8.8438 10.2301 5.6034 0.0494
CL-11 CTRP2 9.1029 11.1199 5.3918 0.2147
⏷ Show the Full List of 27 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuH-6 CTRP2 4.4785 6.7309 1.3121 0.8468
SNU-878 CTRP2 7.2364 9.0104 5.3975 1.1066
SNU-886 CTRP2 7.4694 9.5586 5.2846 1.3723
Hep-G2 CTRP2 7.5038 9.0787 5.5023 0.5858
SNU-182 CTRP2 7.7766 11.8846 4.4108 4.1532
Li-7 CTRP2 7.9692 10.3439 5.2078 1.1212
Hep 3B2.1-7 CTRP2 8.0922 12.0042 4.5486 3.2617
SNU-761 CTRP2 8.3759 9.8857 5.5567 0.1513
SNU-398 CTRP2 8.8757 17.7364 2.3565 10.4935
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 78 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Sq-1 CTRP2 3.8735 5.3028 1.5995 0.3575
SBC-5 CTRP2 7.1195 8.2472 5.658 0.3971
BEN CTRP2 7.1392 8.1549 5.7028 0.2756
RERF-LC-Ad1 CTRP2 7.329 8.4987 5.6521 0.3041
LCLC-103H CTRP2 7.3488 8.8529 5.5208 0.6324
Lu-99 CTRP2 7.3674 9.4707 5.2677 1.4284
NCI-H460 CTRP2 7.4022 9.3559 5.3364 1.1641
CAL-12T CTRP2 7.4475 9.7915 5.1706 1.6897
NCI-H2444 CTRP2 7.4825 8.5665 5.6892 0.1735
NCI-H2286 CTRP2 7.5064 9.5383 5.3129 1.1527
NCI-H226 CTRP2 7.5121 8.9498 5.557 0.4397
NCI-H1155 CTRP2 7.5305 9.2958 5.4267 0.7819
HCC2279 CTRP2 7.66 10.9007 4.794 2.8345
NCI-H520 CTRP2 7.6824 9.9151 5.2434 1.2315
NCI-H2172 CTRP2 7.7253 9.6229 5.3862 0.7679
Calu-3 CTRP2 7.7285 10.5141 5.0079 1.9848
HARA [Human squamous cell lung carcinoma] CTRP2 7.8438 10.3135 5.1573 1.3758
NCI-H2126 CTRP2 7.8718 9.1418 5.6316 0.1598
NCI-H526 CTRP2 7.8825 9.0022 5.6843 0.0909
EPLC-272H CTRP2 7.9045 9.686 5.4425 0.519
Calu-6 CTRP2 7.9358 12.0494 4.4336 3.8714
NCI-H2122 CTRP2 7.9645 9.1315 5.6692 0.094
NCI-H889 CTRP2 7.9682 9.6443 5.4856 0.3925
NCI-H358 CTRP2 7.9685 10.1362 5.2928 0.874
NCI-H1755 CTRP2 7.9807 9.6555 5.4866 0.3853
HCC44 CTRP2 7.9977 11.7416 4.612 3.1321
NCI-H661 CTRP2 8.0021 9.8863 5.4073 0.5548
NCI-H2023 CTRP2 8.0265 9.6056 5.5238 0.2944
EBC-1 CTRP2 8.0276 10.1817 5.3021 0.8113
NCI-H196 CTRP2 8.0678 9.236 5.67 0.0779
NCI-H1581 CTRP2 8.0744 9.6945 5.5102 0.3035
SHP-77 CTRP2 8.0769 9.4377 5.6036 0.1522
NCI-H446 CTRP2 8.1015 9.8647 5.4578 0.3968
NCI-H650 CTRP2 8.1104 9.5345 5.5819 0.1746
NCI-H2405 CTRP2 8.1189 11.8664 4.6266 2.9484
HCC1588 CTRP2 8.1239 9.623 5.5555 0.2107
NCI-H292 CTRP2 8.2146 9.5924 5.6 0.1291
NCI-H2030 CTRP2 8.2284 11.9105 4.6694 2.6824
NCI-H2106 CTRP2 8.247 10.0449 5.45 0.3574
NCI-H524 CTRP2 8.2472 10.0062 5.4643 0.33
HCC1833 CTRP2 8.2635 10.3741 5.3321 0.6055
NCI-H1666 CTRP2 8.2644 9.9149 5.5044 0.254
HCC78 CTRP2 8.3006 10.3721 5.3488 0.549
HCC95 CTRP2 8.3007 9.7315 5.5829 0.287
NCI-H727 CTRP2 8.3073 10.1428 5.438 0.3589
NCI-H1734 CTRP2 8.322 9.8124 5.5625 0.1547
HCC827 CTRP2 8.3248 9.9088 5.5296 0.1989
SK-LU-1 CTRP2 8.3381 10.2868 5.3969 0.429
NCI-H69 CTRP2 8.3431 9.9206 5.5323 0.1908
PC-14 CTRP2 8.3474 10.0065 5.5033 0.2328
NCI-H2087 CTRP2 8.3582 10.1798 5.4447 0.3289
HCC15 CTRP2 8.3877 12.9527 4.2926 3.8783
LOU-NH91 CTRP2 8.3903 10.0623 5.4997 0.2272
HCC1195 CTRP2 8.4019 10.0185 5.5196 0.195
HCC1171 CTRP2 8.4054 10.1479 5.4748 0.2625
NCI-H1184 CTRP2 8.4102 10.1748 5.4669 0.2741
NCI-H1838 CTRP2 8.4269 10.2913 5.431 0.3312
NCI-H1373 CTRP2 8.495 10.1122 5.5212 0.1725
DMS 79 CTRP2 8.511 9.7951 5.635 0.0568
NCI-H2085 CTRP2 8.5182 10.5354 5.3775 0.3999
NCI-H211 CTRP2 8.5524 10.2029 5.5105 0.1745
SW1271 CTRP2 8.5545 10.2395 5.4985 0.1899
NCI-H2228 CTRP2 8.5724 10.8164 5.2944 0.5496
HCC366 CTRP2 8.59 10.3426 5.4753 0.2141
NCI-H1573 CTRP2 8.644 18.2797 1.9345 12.3345
NCI-H441 CTRP2 8.6587 10.4816 5.4518 0.2316
LXF 289 CTRP2 8.6688 10.7545 5.357 0.3863
NCI-H2291 CTRP2 8.6974 10.3582 5.5093 0.1483
NCI-H2009 CTRP2 8.7039 10.5016 5.4616 0.2072
RERF-LC-A1 CTRP2 8.7146 10.1689 5.5798 0.0773
COLO 699 CTRP2 8.7414 11.9269 4.9308 1.397
NCI-H1792 CTRP2 8.7653 10.5046 5.4831 0.1669
HCC2108 CTRP2 8.9637 10.5369 5.5421 0.0802
NCI-H1299 CTRP2 9.0794 10.9195 5.4528 0.1469
NCI-H1355 CTRP2 9.1131 11.0292 5.4271 0.1696
NCI-H1650 CTRP2 9.2147 11.0735 5.4481 0.1314
A-549 CTRP2 9.7698 19.6943 2.0185 10.4661
MOR/CPR CTRP2 13.7861 30.6222 -0.5483 13.2942
⏷ Show the Full List of 78 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TYK-nu CTRP2 4.3805 6.2087 1.4682 0.4553
SNU-840 CTRP2 4.6269 6.3862 1.4991 0.2919
OVISE CTRP2 7.1398 9.0497 5.3266 1.4458
SNU-8 CTRP2 7.5246 8.7739 5.6296 0.2705
SNU-119 CTRP2 7.7205 9.4176 5.4662 0.5562
HEY A8 CTRP2 7.7332 8.9466 5.6488 0.1689
ES2 CTRP2 7.8465 8.9564 5.6872 0.0937
SK-OV-3 CTRP2 7.8692 9.6335 5.4475 0.5247
IGROV-1 CTRP2 8.0982 10.0256 5.3952 0.5367
DOV13 CTRP2 8.1019 9.6934 5.5215 0.2739
ONCO-DG-1 CTRP2 8.1199 9.3043 5.6651 0.0756
OVTOKO CTRP2 8.2719 10.9443 5.1076 1.204
OVK18 CTRP2 8.2892 10.2171 5.4029 0.4359
MCAS CTRP2 8.4317 9.9174 5.5658 0.1301
OVCAR-4 CTRP2 8.4611 10.4441 5.3884 0.3995
FU-OV-1 CTRP2 8.5712 10.4386 5.4338 0.2824
OVCAR-8 CTRP2 8.5819 10.0797 5.5637 0.1085
JHOC-5 CTRP2 8.6242 12.2801 4.7233 2.1324
OAW28 CTRP2 8.6333 10.7719 5.3363 0.4385
Caov-3 CTRP2 8.6812 10.1825 5.5636 0.095
Kuramochi CTRP2 8.7316 10.4844 5.4778 0.18
RMG-I CTRP2 9.0917 11.1892 5.3633 0.256
OVSAHO CTRP2 16.1945 31.1601 0.5962 8.1059
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaTu 8902 CTRP2 3.9671 5.5395 1.5495 0.4424
KP-4 CTRP2 7.2811 9.2874 5.3006 1.3968
SUIT-2 CTRP2 7.6526 9.7259 5.3082 1.0505
Panc 05.04 CTRP2 7.8359 9.5264 5.4745 0.4766
SU.86.86 CTRP2 7.9576 9.3704 5.5825 0.2132
YAPC CTRP2 7.9724 9.5844 5.5099 0.3408
CFPAC-1 CTRP2 8.0135 9.3836 5.5991 0.173
TCC-Pan2 CTRP2 8.0703 9.6541 5.5234 0.2806
SNU-213 CTRP2 8.1476 9.2962 5.6774 0.0618
BxPC-3 CTRP2 8.218 10.6495 5.2023 0.9678
L3.3 CTRP2 8.2224 9.5924 5.6028 0.1244
QGP-1 CTRP2 8.2541 9.4832 5.6513 0.0711
HPAC CTRP2 8.346 10.0908 5.4724 0.2838
HPAF-II CTRP2 8.3701 11.7592 4.8134 2.0548
HuP-T4 CTRP2 8.3817 9.9857 5.5237 0.194
SNU-410 CTRP2 8.4262 10.0542 5.5161 0.1944
KP-3 CTRP2 8.48 10.8297 5.2497 0.6954
PK-59 CTRP2 8.5549 10.6824 5.3377 0.4654
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ACC-MESO-1 CTRP2 8.2446 9.391 5.6789 0.0509
MSTO-211H CTRP2 8.3859 10.1326 5.4727 0.2714
NCI-H2052 CTRP2 8.5014 10.3056 5.4549 0.2678
NCI-H2452 CTRP2 8.5133 10.1514 5.5142 0.1778
NCI-H28 CTRP2 9.0356 10.5715 5.555 0.0641
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
22Rv1 CTRP2 9.0931 11.0374 5.417 0.1851
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 7.9376 8.9028 5.7369 0.0391
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-7951 CTRP2 4.8082 5.9753 4.7135 8.5654
SK-MEL-28 CTRP2 6.6136 10.9164 4.065 7.2797
LOX-IMVI CTRP2 7.4401 9.3935 5.3401 1.1196
COLO 741 CTRP2 7.5647 11.7824 4.322 4.7752
SK-MEL-1 CTRP2 7.6678 8.8149 5.671 0.1518
Hs 936.T CTRP2 7.8134 8.7924 5.7314 0.0555
WM793 CTRP2 7.8321 9.6607 5.4203 0.6121
SK-MEL-30 CTRP2 7.8359 8.9422 5.6883 0.0942
SK-MEL-5 CTRP2 7.9283 9.2797 5.6039 0.1872
IPC-298 CTRP2 7.9684 9.2568 5.6271 0.1441
A-375 CTRP2 7.9734 9.6965 5.468 0.4284
MDA-MB-435S CTRP2 8.0523 9.3782 5.6154 0.1417
G-361 CTRP2 8.0771 9.3482 5.6349 0.1131
Mel Ho CTRP2 8.2357 9.6532 5.5865 0.1416
WM1799 CTRP2 8.2404 9.3405 5.6943 0.0413
SK-MEL-31 CTRP2 8.3471 9.9364 5.5282 0.1957
Hs 852.T CTRP2 8.4775 10.0415 5.5395 0.1529
Mel JuSo CTRP2 8.4782 9.9749 5.5627 0.1256
Hs 944.T CTRP2 8.48 9.9681 5.5657 0.1221
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Rh41 CTRP2 8.3809 9.8751 5.5622 0.1436
RKN CTRP2 8.3937 9.5608 5.6731 0.0422
Rh18 CTRP2 8.5667 10.7619 5.3127 0.5128
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MKN45 CTRP2 6.7915 8.6011 5.3221 1.8605
GSU CTRP2 7.1901 8.1531 5.7249 0.2063
SNU-620 CTRP2 7.4742 8.9226 5.5508 0.4753
AGS CTRP2 7.4998 10.7091 4.7846 3.0573
Fu97 CTRP2 7.5619 9.9599 5.1599 1.6165
ECC12 CTRP2 7.6568 8.7796 5.6794 0.1421
MKN1 CTRP2 7.8414 9.174 5.6085 0.2036
SNU-5 CTRP2 7.855 9.2684 5.5795 0.2494
ECC10 CTRP2 7.878 9.6711 5.4367 0.5464
GSS CTRP2 7.9084 9.0313 5.6835 0.0876
23132/87 CTRP2 8.1639 9.7274 5.5333 0.2351
NUGC-4 CTRP2 8.2273 9.6863 5.5719 0.1622
SNU-668 CTRP2 8.3574 9.4074 5.7113 0.0251
SNU-719 CTRP2 8.566 10.4313 5.4345 0.2828
NUGC-3 CTRP2 8.5854 10.1109 5.5543 0.1175
NCI-N87 CTRP2 8.9469 10.8793 5.4187 0.2122
MKN74 CTRP2 8.969 10.7248 5.4803 0.1353
KE-39 CTRP2 9.5614 12.0237 5.2436 0.3169
SNU-1077 CTRP2 8.6416 10.1805 5.5504 0.113
SNG-M CTRP2 9.0526 10.7262 5.5091 0.0968
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-62 CTRP2 7.6189 9 5.5836 0.3288
B-CPAP CTRP2 7.833 9.2136 5.5909 0.2362
8305C CTRP2 8.0678 10.4862 5.1972 1.0827
BHT-101 CTRP2 8.1028 9.6825 5.5258 0.2659
CGTH-W-1 CTRP2 8.2539 9.5308 5.6351 0.0855
TT CTRP2 8.3281 9.8307 5.5583 0.1588
8505C CTRP2 8.3496 10.4371 5.3448 0.5359
ML-1 [Human leukemia] CTRP2 8.6437 10.358 5.4898 0.1825
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-4 CTRP2 4.4302 5.8819 1.6032 0.166
SNU-1076 CTRP2 7.4599 9.188 5.4367 0.8019
SCC-25 CTRP2 7.6647 9.516 5.4009 0.7658
BHY CTRP2 7.7529 9.373 5.4978 0.4617
HSC-3 CTRP2 7.8771 19.2779 0.886 17.0723
YD-10B CTRP2 8.0974 9.2765 5.6666 0.0771
SNU-899 CTRP2 8.167 9.5015 5.6143 0.121
Detroit 562 CTRP2 8.2763 18.0365 1.7914 13.3983
SNU-46 CTRP2 8.4867 10.3834 5.421 0.3299
SNU-1041 CTRP2 8.6402 10.2797 5.5157 0.151
SNU-1066 CTRP2 8.6978 10.302 5.5288 0.1267
SNU-1214 CTRP2 8.9586 10.737 5.4724 0.1453
YD-8 CTRP2 8.9781 10.846 5.4418 0.1768
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
639V CTRP2 7.4753 8.7164 5.6309 0.2875
CAL-29 CTRP2 7.6105 9.0275 5.5696 0.3631
KU-19-19 CTRP2 7.6203 9.1982 5.5077 0.5055
253J CTRP2 7.6828 9.4094 5.4523 0.6134
253J-BV CTRP2 7.6841 8.9146 5.6414 0.1944
JMSU-1 CTRP2 7.8352 9.5088 5.481 0.4617
HT-1376 CTRP2 8.0551 10.1497 5.3275 0.7272
BFTC-905 CTRP2 8.1282 9.427 5.626 0.1143
VM-CUB-1 CTRP2 8.3472 10.1255 5.4602 0.3046
TCCSUP CTRP2 8.5163 9.9097 5.5984 0.0848
RT-4 CTRP2 8.5308 10.2938 5.4703 0.2358
5637 CTRP2 8.5878 10.7271 5.3344 0.4592
SW1710 CTRP2 8.7832 10.4603 5.5049 0.1387
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 7.2303 8.2234 5.715 0.2108

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ifosfamide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
LEE011 DMMX75K Moderate Decreased metabolism of Ifosfamide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [17]
Coadministration of a Drug Treating the Disease Different from Ifosfamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Ifosfamide caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [18]
Arn-509 DMT81LZ Moderate Increased metabolism of Ifosfamide caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [19]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Ifosfamide and Inotersen. Amyloidosis [5D00] [19]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Ifosfamide and Roflumilast. Asthma [CA23] [19]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Ifosfamide caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [20]
Sparfloxacin DMB4HCT Minor Decreased absorption of Ifosfamide due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [21]
ABT-492 DMJFD2I Minor Decreased absorption of Ifosfamide due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [21]
Alpelisib DMEXMYK Moderate Increased metabolism of Ifosfamide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Ifosfamide and Iodipamide. Cholelithiasis [DC11] [22]
MK-8228 DMOB58Q Moderate Decreased metabolism of Ifosfamide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [23]
Cenobamate DM8KLU9 Moderate Increased metabolism of Ifosfamide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [24]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ifosfamide caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Rufinamide DMWE60C Moderate Increased metabolism of Ifosfamide caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [19]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Ifosfamide caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Darunavir DMN3GCH Moderate Decreased metabolism of Ifosfamide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [27]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Ifosfamide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [28]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Ifosfamide and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [18]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Ifosfamide caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [29]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Ifosfamide and Denosumab. Low bone mass disorder [FB83] [30]
Ceritinib DMB920Z Moderate Decreased metabolism of Ifosfamide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [19]
PF-06463922 DMKM7EW Moderate Increased metabolism of Ifosfamide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [31]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Ifosfamide and Tecfidera. Multiple sclerosis [8A40] [32]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Ifosfamide and Siponimod. Multiple sclerosis [8A40] [18]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Ifosfamide and Fingolimod. Multiple sclerosis [8A40] [33]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Ifosfamide and Ocrelizumab. Multiple sclerosis [8A40] [34]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Ifosfamide and Ozanimod. Multiple sclerosis [8A40] [19]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Ifosfamide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [35]
Abametapir DM2RX0I Moderate Decreased metabolism of Ifosfamide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [36]
Lefamulin DME6G97 Moderate Decreased metabolism of Ifosfamide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [37]
Enzalutamide DMGL19D Moderate Increased metabolism of Ifosfamide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [38]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Ifosfamide and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [39]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Ifosfamide and Canakinumab. Rheumatoid arthritis [FA20] [40]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Ifosfamide and Rilonacept. Rheumatoid arthritis [FA20] [40]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Ifosfamide and Golimumab. Rheumatoid arthritis [FA20] [41]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Ifosfamide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [42]
Pitolisant DM8RFNJ Moderate Increased metabolism of Ifosfamide caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [19]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Ifosfamide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [43]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Ifosfamide and Plazomicin. Urinary tract infection [GC08] [18]
Valganciclovir DMS2IUH Moderate Increased risk of nephrotoxicity by the combination of Ifosfamide and Valganciclovir. Virus infection [1A24-1D9Z] [18]
⏷ Show the Full List of 39 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Water E00035 962 Solvent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ifosfamide 3gm/vial injectable 3gm/vial Injectable Injection
Ifosfamide 1gm/vial injectable 1gm/vial Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Ifosfamide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7201).
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
9 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
10 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
11 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
12 Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
13 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
14 A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
15 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
16 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
17 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
18 Cerner Multum, Inc. "Australian Product Information.".
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
21 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
22 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
23 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
24 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
25 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
26 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
27 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
28 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
29 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
30 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
31 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
33 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
34 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
35 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
36 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
37 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
38 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
39 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
40 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
41 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
42 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
43 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.